XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY-BASED COMPENSATION (Tables)
3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Payment Arrangement, Expensed and Capitalized, Amount The Company’s equity-based compensation expense, included within selling, general and administrative expenses in the condensed consolidated statements of operations and comprehensive income, was as follows (in thousands):
Three Months Ended
March 31,
20232022
Restricted Stock$5,210 $4,637 
SARs375 568 
Total$5,585 $5,205 
Schedule of Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity A summary of Restricted Stock activity during the three months ended March 31, 2023 is as follows:
Restricted
Stock
Weighted
Average Grant
Date Fair Value
Per Share
Outstanding as of December 31, 202242,467$1,611.99 
Granted65,857$696.08 
Forfeited(6,316)$1,757.08 
Vested and issued(9,648)$1,586.62 
Outstanding as of March 31, 202392,360$951.63 
Vested and deferred as of March 31, 20236,726$866.52 
Schedule of Share-Based Payment Award, Restricted Stock Valuation Assumptions
The significant inputs and resulting weighted average grant date fair value for market-based award grants were as follows:
2023
Risk-free interest rate4.1 %
Expected volatility39.1 %
Simulation term2.99 years
Weighted average grant date fair value$774.30
Schedule of Share-Based Payment Arrangement, Stock Appreciation Right, Activity A summary of SARs activity during the three months ended March 31, 2023 is as follows:
Stock
Appreciation
Rights
Weighted
Average
Exercise
Price
Weighted
Average
Grant
Date Fair
Value
Aggregate
Intrinsic
Value
(in thousands)
Weighted
Average
Remaining
Contractual
Term
(in years)
Outstanding as of December 31, 202241,115$1,072.88 $262.99 $591 6.1
Forfeited(375)$1,274.05 $280.58 
Outstanding as of March 31, 202340,740$1,071.03 $262.83 $494 5.8
Exercisable as of March 31, 202332,990$908.39 $217.83 $494 5.4